Teva Breaks Out OTC Sales Figures In Bid To Play Up Diversification
By
Dan Schiff / Email the Author / “The Tan Sheet” Feb. 20, 2012, Vol. 20, No. 08
OTCs / Word Count: 449 / Article # 05120220029
Executive Summary
Teva Pharmaceutical Industries reported OTC product sales for the first time Feb. 15. The Jerusalem firm said OTC net revenue was $765 million in 2011, up 54.2% and attributable largely to the acquisition of German firm ratiopharm and the PGT Healthcare joint venture with Procter & Gamble.
Already a Subscriber?
Log in for complete access.
Log In
Questions?
Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.